Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Biomarkers of Renal Health in Patients (pts) Treated with Fedratinib in the FREEDOM and FREEDOM2 Trials

Vikas Gupta, Yizhe Chen, Patrick Brown, Danny Jeyaraju, Moshe Talpaz, Ruben Mesa, Richard Pilot, Christopher Hernandez, Jia Wang, Jean-Jacques Kiladjian, Alessandro Vannucchi, Claire Harrison

Blood (2024) 144 (Supplement 1): 6623.

https://doi.org/10.1182/blood-2024-194223

Published: 2024

Journal Articles

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial

Haifa Kathrin Al-Ali, Claire Harrison, Ruben Mesa, Moshe Talpaz, Blanca Xicoy, Francesco Passamonti, Alessandro Vannucchi, Patrick Brown, Christopher Hernandez, Jia Wang, Jun He, Jean-Jacques Kiladjian

Blood (2024) 144 (Supplement 1): 482.

https://doi.org/10.1182/blood-2024-193645

Published: 2024

Journal Articles

Venetoclax Plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for Elderly or Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia: A Multicenter, Prospective Study

Hongbing Ma, Yiwen Du, Jianjun Li, Jin Rao, Yong Guo, Yunfan Yang, Duanzhong Zhang, Jia Wang, Yi Liao, Yuping Gong

Blood (2024) 144 (Supplement 1): 2898.

https://doi.org/10.1182/blood-2024-202318

Published: 2024

Journal Articles

Long-Term Efficacy Observation of Anti-BCMA CAR-T Cell Therapy Combined with Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma with Extramedullary Disease

QI Deng, Xin Li, Qing Li, Jia Wang, Juan Mu, Rui Cui

Blood (2024) 144 (Supplement 1): 4763.

https://doi.org/10.1182/blood-2024-205268

Published: 2024

Journal Articles

Pretreatment with BTK Inhibitors Could Improve the Sensitivity of DLBCL Cells to CAR-T Cells in Co-Culture System By Down-Regulating the Polarization of M2 Macrophages

Yao Qi, Jia Wang, Xin Li, Juan Mu, Rui Cui, QI Deng

Blood (2024) 144 (Supplement 1): 1625.

https://doi.org/10.1182/blood-2024-206729

Published: 2024

Journal Articles

Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy

Blood (2024) 143 (18): 1825–1836.

https://doi.org/10.1182/blood.2023019706

Published: 2024

Includes: Supplemental data

Journal Articles

Comparison of Efficacy and Side Effects of BTK Inhibitors for Different Duration As a Bridging Therapy before Anti-CD19-CAR T-Cell Therapy in Patients with R/R DLBCL

QI Deng, Jia Wang, Rui Cui, Juan Mu, Xin Li, Qing Li, Lugui Qiu

Blood (2023) 142 (Supplement 1): 3482.

https://doi.org/10.1182/blood-2023-182855

Published: 2023

Journal Articles

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study

Claire N Harrison, Ruben Mesa, Moshe Talpaz, Haifa Kathrin Al-Ali, Blanca Xicoy, Francesco Passamonti, Francesca Palandri, Giulia Benevolo, Alessandro M. Vannucchi, Clemence Mediavilla, Alessandra Iurlo, InHo Kim, Patrick Brown, Christopher Hernandez, Shelonitda Rose, Jia Wang, Jean-Jacques Kiladjian

Blood (2023) 142 (Supplement 1): 3204.

https://doi.org/10.1182/blood-2023-173391

Published: 2023

Journal Articles

Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker Analysis from the Phase 3 FREEDOM2 Trial

Danny Jeyaraju, Sheida Hayati, Jia Wang, Claire N Harrison, Jean-Jacques Kiladjian, Christopher Hernandez, Patrick Brown, Daniel Lopes De Menezes, Anita K. Gandhi, Rajasekhar N.V.S. Suragani

Blood (2023) 142 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2023-180419

Published: 2023

Journal Articles

Efficacy and Safety of Ino Combined with Reduce Dose R-GDP Regimen in Patients with Relapsed/Refractory B-Cell NHL in China

Xin Li, Rui Cui, Jia Wang, Juan Mu, Yili Jiang, Jingyi Li, Lugui Qiu, QI Deng

Blood (2023) 142 (Supplement 1): 6880.

https://doi.org/10.1182/blood-2023-182822

Published: 2023

Journal Articles

The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment

Blood (2023) 142 (10): 903–917.

https://doi.org/10.1182/blood.2022019537

Published: 2023

Includes: Supplemental data

Journal Articles

Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR/Cas9-Modified Autologous CD34 + Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent β-Thalassemia

Blood (2022) 140 (Supplement 1): 10652–10653.

https://doi.org/10.1182/blood-2022-166365

Published: 2022

Journal Articles

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, Ruben Mesa, Claire Harrison, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, H. Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J. Mattison, Carole B. Miller, Vinod Parameswaran, Patricia Martin-Regueira, Christopher Hernandez, Jia Wang, Moshe Talpaz

Blood (2022) 140 (Supplement 1): 3935–3937.

https://doi.org/10.1182/blood-2022-156669

Published: 2022

Journal Articles

CD19 CAR-T Cells Treatment Conferred a Sustained Remission in Patients with Chemotherapy-Refractory MRD in B-ALL

Blood (2020) 136 (Supplement 1): 48.

https://doi.org/10.1182/blood-2020-140431

Published: 2020

Journal Articles

Humanized CD19 CAR-T Cell Combined with Multiple Combination Treatments in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Jia Wang, Ji-jun Yuan, Juan Mu, Qing Li, Nan Mou, Zhen-xing Yang, Wei Li, Lanfang Li, Peiqi Zhao, Xianhuo Wang, Yedi Pu, Huilai Zhang, MD, Qi Deng

Blood (2019) 134 (Supplement_1): 5346.

https://doi.org/10.1182/blood-2019-127896

Published: 2019

Journal Articles

Anti-CD19-CAR T-Cell from Patients Relapsed after Allo-HSCT with a Low Level of Donor Chimerism Restored to Complete Donor Chimerism: Successful Cases and Analysis

Qing Li, Juan Mu, Zhen-xing Yang, Nan Mou, Jia Wang, Ji-jun Yuan, Yanyu Jiang, Meng Juanxia, Qi Deng

Blood (2019) 134 (Supplement_1): 5628.

https://doi.org/10.1182/blood-2019-127850

Published: 2019

Journal Articles

Embryonic and hematopoietic stem cells express a novel SH2–containing inositol 5′-phosphatase isoform that partners with the Grb2 adapter protein

Zheng Tu, John M. Ninos, Zhengyu Ma, Jia-Wang Wang, Maria P. Lemos, Caroline Desponts, Tomar Ghansah, Julie M. Howson, William G. Kerr

Blood (2001) 98 (7): 2028–2038.

https://doi.org/10.1182/blood.V98.7.2028

Published: 2001

NARROW

Biomarkers of Renal Health in Patients (pts) Treated with Fedratinib in the FREEDOM and FREEDOM2 Trials

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial

Venetoclax Plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for Elderly or Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia: A Multicenter, Prospective Study

Long-Term Efficacy Observation of Anti-BCMA CAR-T Cell Therapy Combined with Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma with Extramedullary Disease

Pretreatment with BTK Inhibitors Could Improve the Sensitivity of DLBCL Cells to CAR-T Cells in Co-Culture System By Down-Regulating the Polarization of M2 Macrophages

Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy

Comparison of Efficacy and Side Effects of BTK Inhibitors for Different Duration As a Bridging Therapy before Anti-CD19-CAR T-Cell Therapy in Patients with R/R DLBCL

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study

Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker Analysis from the Phase 3 FREEDOM2 Trial

Efficacy and Safety of Ino Combined with Reduce Dose R-GDP Regimen in Patients with Relapsed/Refractory B-Cell NHL in China

The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment

Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR/Cas9-Modified Autologous CD34 + Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent β-Thalassemia

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

CD19 CAR-T Cells Treatment Conferred a Sustained Remission in Patients with Chemotherapy-Refractory MRD in B-ALL

Humanized CD19 CAR-T Cell Combined with Multiple Combination Treatments in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Anti-CD19-CAR T-Cell from Patients Relapsed after Allo-HSCT with a Low Level of Donor Chimerism Restored to Complete Donor Chimerism: Successful Cases and Analysis

Embryonic and hematopoietic stem cells express a novel SH2–containing inositol 5′-phosphatase isoform that partners with the Grb2 adapter protein

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only